Amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole in rodent feed and water: Effects of compounding on antibiotic stability

Journal of the American Association for Laboratory Animal Science

Volumn 46, Issue 5, 2007, Pages 26-32

  McIntyre, Alyssa R ^a,c   Lipman, Neil S ^a,b  

^a Tri Institutional Training Program in Computational Biology and Medicine   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLAVULANIC ACID; COTRIMOXAZOLE; AMOXICILLIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; ELECTROSPRAY MASS SPECTROMETRY; FLUID INTAKE; FOOD INTAKE; GAMMA IRRADIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PH MEASUREMENT; REVERSE OSMOSIS; RODENT; ANIMAL; ANIMAL FOOD; ANIMAL HUSBANDRY; C57BL MOUSE; DRUG FORMULATION; MALE; METHODOLOGY; WATER SUPPLY;

MUS; RODENTIA;

AMOXICILLIN; ANIMAL FEED; ANIMAL HUSBANDRY; ANIMALS; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLAVULANIC ACID; DRUG COMPOUNDING; DRUG STABILITY; MALE; MICE; MICE, INBRED C57BL; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; WATER SUPPLY;

EID: 36048962705     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Altholtz LY, LaPerle KMD, Quimby FW. 2006. Dose-dependant hypothyroidism in mice induced by commercial trimethoprimsulfamethoxazole rodent feed. Comp Med 56:395-401
2. American Veterinary Medicine Association [Internet]. 2005. AVMA position statements: compounding [cited 26 Oct 2006]. Available from http://www.avma.org/issues/drugs/compounding/compounding.asp.
3. Amoxicillin-Clavulanate Potassium Powder for Oral Suspension and Chewable Tablets [Package insert]. 2005. Philadelphia PA: Penn Labs.
4. Chesajimenez J, Peris JE, Torresmolina F, Granero L. 1994. Low bioavailability of amoxicillin in rats as a consequence of presystemic degradation in the intestine. Antimicrob Agents Chemother 38:842-847.
5. Cohn LA, Weber AF, Kaplan M, Smith AL. 2000. Effect of chloramphenicol administration in drinking water on predictable steady-state serum concentrations of the drug in mice. Comp Med 50:56-58.
6. Conole J, Wilkinson MJ, McKellar QA. 2003. Some observations on the pharmacological properties of ivermectin during treatment of a mite infestation in mice. Contemp Top Lab Anim Sci 42(4):42-44.
7. Drusano GL. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 36(Suppl 1):S42-S50.
8. Drusano GL, Louie A, Deziel M, Gumbo T. 2006. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis 42:525-532.
9. Foltz CJ, Fox JG, Yan L, Shames B. 1996. Evaluation of various oral antimicrobial formulations for eradication of Helicobacter hepaticus. Lab Anim Sci 46:193-197.
10. Goelz MF, Thigpen JE, Mahler J, Rogers WP, Locklear J, Weigler BJ, Forsythe DB. 1996. Efficacy of various therapeutic regimens in eliminating Pasteurella pneumotropica from the mouse. Lab Anim Sci 46:280-285.
11. Gould IM, Mackenzie FM. 2002. Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration. Symp Ser Soc Appl Microbiol 92:78S-84S
12. Hawk CT, Leary SL, Morris TH. 2005. Anti-infectives. In: Hawk CT, Leary SL, Morris TH, editors. Formulary for laboratory animals, 3rd ed. Ames (IA): Blackwell Publishing. p 71-106.
13. Hayes JM, Eichman J, Katz T, Gilewicz R. 2003. Stability of florfenicol in drinking water. J AOAC Int 86:22-29.
14. Jacoby RO, Fox JG, Davisson M. 2002. Biology and diseases of mice. In: Fox JG, Anderson LC, Loew FM, Quimby FW, editors. Laboratory animal medicine, 2nd ed. San Diego (CA): Academic Press. p 35-120.
15. Jury J, Gee LC, Delaney KH, Perdue MH, Bonner RA. 2005. Eradication of Helicobacter spp. from a rat breeding colony. Contemp Top Lab Anim Sci 44(4):8-11.
16. Lewis R [Internet]. 1995. The rise of antibiotic-resistant infections. FDA consumer magazine [cited 10 Oct 2006]. Available from http://www.fda.gov/fdac/795_toc.html.
17. Lust E. 2004. Compounding for animal patients: contemporary issues. J Am Pharm Assoc (2003) 44:375-384.
18. McKellar QA, Sanchez Bruni SF, Jones DG. 2004. Pharmacokinetic-pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther 27:503-514.
19. Mehta AC, Hart-Davies S, Payne J, Lacey RW. 1994. Stability of amoxycillin and potassium clavulanate in co-amoxiclav oral suspension. J Clin Pharm Ther 19:313-315.
20. Merck Index [Internet]. c2007. Merck monograph no. 09709: trimethoprim [cited 5 May 2007]. Available from http://themerckindex. cambridgesoft.com/themerckindex.
21. Mickley AG, Hoxha ZH, Biada JM, Kenmuir CK, Bacik SE. 2006. Acetaminophen self-administered in the drinking water increases the pain threshold of rats (Rattus norvegicus). JAALAS 45(5):48-54.
22. Moore TD, Horton R, Utrup LJ, Miller LA, Poupard JA. 1996. Stability of amoxicillin-clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay. J Clin Microbiol 34:1321-1322.
23. National Research Council. 1996. Guide for the care and use of laboratory animals. Washington (DC): National Academy Press.
24. Papich MG. 2005. Drug compounding for veterinary patients. AAPS J 7:E281-E287.
25. Plumb DC. 1994. Do veterinarians have the training and equipment to compound drugs? J Am Vet Med Assoc 205:268-269.
26. Rybak MJ. 2006. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 119(6 Suppl 1):S37-S44; discussion S62-S70.
27. Smith SV, Gould IM. 2004. Optimization of antibiotic dosing schedules in light of increasing antibiotic resistance. Expert Rev Anti Infect Ther 2:227-234.
28. Stroebel V. 2006. Personal communication.
29. Sulfamethoxazole and Trimethoprim Oral Suspension [Package insert]. 2005. Amityville (NY): Hi-Tech Pharmacal.
30. Sumano H, Hernandez L, Gutierrez L, Bernda-Bernad MJ. 2005. Sustained availability of trimethoprim in drinking water to achieve higher plasma sulphonamide-trimethoprim antibacterial activity in broilers. Br Poult Sci 46:114-118.
31. Taconic Labs [Internet]. 2007. Notification to all recipients of p47 PHOX knockout Mice NIAD emerging Line #004227-M [cited 3 March 2007]. Available from http://www.taconic.com/wmspage.cfm?parm1=1342.
32. Tordoff MG, Bachmanov AA [Internet]. 2001. Food intakes, water intakes, and spout side preferences. MPD:63 Mouse Phenome Database [cited 14 June 2005]. Available from http://www.jax.org/phenome.
33. Tsuji A, Nakashima E, Hamano S, Yamana T. 1978. Physiochemical properties of amphoteric β-lactam antibiotics: stability, solubility, and dissolution behavior of amino penicillins as a function of pH. J Pharm Sci 67:1059-1066.
34. United States Code of Federal Regulations [Internet]. 2006. Title 21 part 530 §30 Extralabel drug use in animals [cited 1 Nov 2006]. Available from http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?CFRPart=530.
35. United States Food and Drug Administration [Internet]. 2003. Compliance policy guide. Compounding of drugs for use in animals [cited 30 Oct 2006]. Available from http://www.fda.gov/ora/compliance_ref/cpg/cpgvet/cpg608- 400.html.
36. United States Pharmacopeiea [Internet]. c2007. US Pharmacopeiea description and solubility [cited 25 Oct 2006]. Available from http://www.uspnf.com/uspnf/pub/index?usp=29&nf=24&s=2.
37. United States Pharmacopeiea [Internet]. c2007. 1075 Good compounding practices [cited 31 Oct 2006]. Available from http://www.uspnf.com/ uspnf/pub/data/v29242/usp29nf24s2_c1075.xml.
38. United States Pharmacopeiea [Internet]. c2007. USP monographs: amoxicillin [cited 13 Oct 2006]. Available from http://www.uspnf.com/uspnf/pub/ data/v29242/usp29nf24s2_m4100.xml.
39. United States Pharmacopeiea [Internet]. c2007. USP monographs: clavulanate potassium [cited 13 Oct 2006]. Available from http://www.uspnf.com/ uspnf/pub/data/v29242/usp29nf24s2_m1800.xml.
40. United States Pharmacopeiea [Internet]. c2007. USP material safety data sheet: sulfamethoxazole [cited 2007 May 5]. Available from http://www.usp.org/pdf/EN/referenceStandards/msds/1631001.pdf.
41. Valvo L, Manna L, AIimenti R, Alimonti S, Bertocchi P, Ciranni E. 1999. Amoxicillin sodium-potassium clavulanate: evaluation of gamma radiation induced effects by liquid chromatography on both the individual drugs and their combination. J Pharm Biomed Anal 21:9-14.
42. Walzer PD, Brunck J, Steele P, White M, Linke MJ, Sidman CL. 1997. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother 41:251-258.
43. Walzer PD, Kim CK, Linke MJ, Pogue CL, Huerkamp MJ, Chrisp CE, Lerro AV, Wixson SK, Hall E, Shultz LD. 1989. Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice. Infect Immun 57:62-70
44. Weber DJ, Tolkoff-Rubin NE, Rubin RH. 1984. Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy, and adverse effects. Pharmacotherapy 4:122-136.
45. Weber JT. 2005. Appropriate use of antimicrobial drugs: a better prescription is needed. J Am Med Assoc 294:2354-2356.
46. Woodnutt G. 2000. Pharmacodynamics to combat resistance. J Antimicrob Chemother 46(Suppl T1):25-31.
47. Woodnutt G, Berry V. 1999. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 43:29-34.
48. Yoon KH, Lee SY, Kim W, Park JS, Kim HJ. 2004. Simultaneous determination of amoxicillin and clavulanic acid in human plasma by HPLC-ESI mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 813:121-127.